Business Ethics in the Healthcare Industry

Newscasts and social networks denounce fraud and professional dishonesty in the healthcare domain quite frequently, even though a few of these are groundless fake news and even scams. This book aims a scientific approach to all forms of fraud, misconduct, and breach of ethics in the healthcare business. Chapters will be written by respected professors worldwide, emphasizing not sensation and impact but a reasoned and scholarly description of the problems, roots, impacts and solutions.

A systematic analysis of each ecosystem and the most prevalent forms of misconduct and unethical procedures will be provided. This encompasses drug manufacturers, health insurance and health maintenance organizations, including telehealth and internet healthcare providers, analytical testing services for clinical services and consumer health purposes, including genomics and other omics sequencing, producers and distributors of surgical material, imaging apparatuses and general hospital equipment, personal electronic health monitoring devices, and robotic developers for assistance to small children, the handicapped, the elderly and other medically relevant populations. The emphasis will be descriptive and constructive, about the roots of the issue and involved environments, agents and stakeholders, and concerning what can and should be done to curb the prevalence and consequences of abuses. Medical, scientific, and ethical authorities will be most of the contributors; however, social professionals, lawyers, and economists will help from different vantage points to enrich the messages.

Students, trainees, and professionals are the target, primarily in medicine, pharmacy, nursing, and nutrition, along with business administrators, accountants, and lawyers. All areas of the healthcare business are envisaged, encompassing the related fields of law, social sciences, and the rapidly growing ethics/bioethics field. Policy makers and government agencies should not be overlooked.

Provides state of the art guidance on healthcare business fraud, dishonesty, misconduct, and corruption Features expert recommendations for prevention and management of conflicts of interest in the healthcare industry Discusses ethical framework for pharmaceutical and other industries for prevention

Autorentext

Joel Faintuch MD is a gastrointestinal surgeon, and former International Guest Fellow of the American College of Surgeons. He is Honorary Fellow of three foreign Surgical Societies and has served as Visiting Professor at the University of Maastricht. During his career, he has been interested in a variety of subjects, including nutrition, metabolism, obesity, and ethics in research. He was the introducer of Parenteral and Enteral Nutrition in Brazil and South America and a founding member of different medical societies. In the last 20 years, he has acted as vice-president of the Ethics in Research Committee, Hospital das Clinicas and Sao Paulo University Medical School, which is the oldest and largest in Latin America. Dr. Faintuch is the author of over 270 articles in peer-reviewed journals, along with 12 books, three theses, over 200 chapters in books, and other publications.

Salomao Faintuch MD is a radiologist and Clinical Director of Vascular and Interventional Radiology at Beth Israel Deaconess Medical Center, Harvard Medical School. He has authored more than 50 articles in peer-reviewed journals, along with 8 Society Guidelines and Standards of Practice. He is a Radiological Society of North America Research Scholar, has participated in eight National Society Committees and is a member of the Editorial Board of three international journals.

Klappentext

Business ethics in healthcare are often restricted to broad, non-specific topics such as white-collar crime, insider trading, corporate social responsibility, reputation management, and social responsiveness. While these issues are certainly relevant, they are not unique to the healthcare sector. In contrast, the most pressing ethical challenges in healthcare frequently involve personal harm and misconduct, directly affecting patients, students, and professionals - who may be both victims and perpetrators. On the other side, institutions, manufacturers, and providers - including company officials, employees, and the healthcare organizations themselves - also play a critical role as problems emerge, typically responding for both their genesis and solution.

Few publications have addressed such topics, notably with an up-to-date, practical and effective approach. This book has assembled a first-class international team to provide the most reliable and accessible insights available in the field. Physicians, nurses, pharmacists, psychologists, and other healthcare professionals - as well as graduate and postgraduate students, business leaders, and government officials - will appreciate the clarity and relevance of the real-world topics discussed and analyzed throughout this work.

Inhalt

1. Health equity, diversity and inclusion: Critical foundations for ethical leadership.- 2. Should doctors work with the pharmaceutical industry ?.- 3. Industry influence on healthcare provider behaviors.- 4. Promoting world health with equity: From patents to impact funds.- 5. Nursing homes and end of life care: An ethical paradigm ?.- 6. Thick concepts and pharmaceutical industry corruption.- 7. Fake drugs, real concerns.- 8. Ethics of off label marketing of drugs: Patient safety versus commercial profits.- 9. Small pharma ethical behavior.- 10. Informational quarantine: Should it be punishable to spread medical disinformation during a pandemic ?.- 11. Industry payments.- 12. Global implementation of tobacco demand reduction measures specified in framework convention on tobacco control .- 13. Understanding the problems of medical student exposure to pharmaceutical marketing.- 14. Ten challenges to healthcare business ethics in the XXI century.- 15. Ethics and sustainability in food production and consumption. The vegan paradigm .- 16. Bribery in Japan´s medical device sector.- 17. Risk of recall among medical devices undergoing US FDA 510(k) clearance and premarket approval.- 18. Implant ethics between business and the clinic.- 19. Xenotransplation.- 20. Internet links to illegal pharmacies.- 21. Illicit online pharmacies.- 22. Dietary supplements adulterated with drugs and contaminated with heavy metals.- 23. Experimental therapies with the application of the EU Hospital Exemption Regulation for Advanced Therapy Medicinal Products European and Polish perspectives.- 24. Ethics in dental services: business as usual ?.- 25. Advertisement techniques and biologic treatment in psoriasis.- 26. Keeping medical science trustworthy: the threat by predatory journals.- 27. The ethics of  internet healthcare crowdfunding.- 28. The complex dynamics of decision-making at the end of life in the intensive care unit.- 29. Medical Board transparency regarding physician sexual misconduct.- 30. Abusive supervision, nursing workforce, and patient safery outcomes.- 31. Dignity in end-of-life care in hospice.- 32. Ethical issues in clinical decision-making about involuntary psychiatric treatment.- 33. Conflicts of interest in biomedical, social and environmental aspects of health.- 34. Ethics of sustainability in healthcare.- 35. Energy conservation and sustainability in the clinical laboratory.- 36. Private equity and its increasing role in the US.- 37. Racism and healthcare in Germany.- 38. Access to healthcare by migrants.- 39. Sexual and reproductive health care for migrant women.- 40. Addressing Socioeconomic Disparities in Healthcare Outcomes of Children  in the United States of America.- 41. Ethical Challenges in Mental Healthcare for South Asian, Particularly Sikh, Survivors of Domestic Abuse .- 42. Inclusive Diversity Management in Healthcare: The Ethics of I…